26.38
Schlusskurs vom Vortag:
$26.86
Offen:
$27.17
24-Stunden-Volumen:
117.09K
Relative Volume:
0.31
Marktkapitalisierung:
$313.62M
Einnahmen:
$47.11M
Nettoeinkommen (Verlust:
$15.64M
KGV:
35.39
EPS:
0.7455
Netto-Cashflow:
$-15.89M
1W Leistung:
+1.54%
1M Leistung:
+9.87%
6M Leistung:
-29.50%
1J Leistung:
+30.14%
Xoma Royalty Corp Stock (XOMA) Company Profile
Firmenname
Xoma Royalty Corp
Sektor
Branche
Telefon
510-204-7239
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
XOMA
Xoma Royalty Corp
|
26.38 | 319.32M | 47.11M | 15.64M | -15.89M | 0.7455 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | The Benchmark Company | Buy |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2021-09-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-06-29 | Eingeleitet | Aegis Capital | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2017-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-11 | Bestätigt | Wedbush | Outperform |
| 2015-07-23 | Herabstufung | Jefferies | Buy → Hold |
| 2015-07-22 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Fortgesetzt | ROTH Capital | Buy |
| 2014-04-29 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-11 | Herabstufung | MLV & Co | Buy → Hold |
| 2014-03-05 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-10-31 | Bestätigt | MLV & Co | Buy |
| 2013-05-09 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-14 | Eingeleitet | Cowen & Co | Outperform |
| 2011-03-31 | Bestätigt | MLV Capital | Buy |
| 2011-03-23 | Bestätigt | RBC Capital Mkts | Outperform |
| 2011-01-06 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-01-04 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
FMR LLC's Strategic Acquisition of XOMA Royalty Corp Shares - GuruFocus
XOMA Royalty (NASDAQ:XOMA) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 - The Manila Times
XOMA Royalty (XOMA) to Release Earnings on Monday - MarketBeat
Layoff Watch: Why is XOMA Royalty Corporation stock going downJuly 2025 WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update - MarketBeat
XOMA (NASDAQ: XOMA) details 2025 royalty cash, buybacks and litigation costs - Stock Titan
LVTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
XOMA Royalty Corporation (NASDAQ:XOMA) Receives $60.60 Average Price Target from Brokerages - Defense World
What Analysts Are Saying About XOMA Royalty Stock - Sahm
Leerink raises Xoma stock price target on royalty outlook - Investing.com
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
MURAMural Oncology PLC Latest Stock News & Market Updates - Stock Titan
XOMA Royalty to Present at Investor Conferences in March - 富途牛牛
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right - Intellectia AI
Biotech royalty player XOMA lines up March investor talks - Stock Titan
Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 27.4% - MarketBeat
What drives XOMA Royalty Corporation’s stock priceJuly 2025 Gainers & Smart Swing Trading Alerts - mfd.ru
XOMA Royalty (NASDAQ:XOMA) Upgraded by TD Cowen to "Hold" Rating - MarketBeat
Why XOMA Royalty Corporation stock is rated strong buyJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
XOMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com South Africa
Buyback Watch: What drives XOMA Royalty Corporations stock priceJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research - Defense World
XOMA Royalty (NASDAQ:XOMA) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
XOMA Royalty’s Preferreds Still Offer Compelling Income Despite Call Risk (NASDAQ:XOMA) - Seeking Alpha
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
XOMA Completes Acquisition and Delisting of Generation Bio - TipRanks
XOMA Royalty Completes Generation Bio Acquisition and Merger - TipRanks
XOMA Royalty Corporation Completes Acquisition of Generation Bio Co. Through Tender Offer - Quiver Quantitative
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. - GlobeNewswire
Published on: 2026-02-09 02:34:15 - baoquankhu1.vn
Gainers Report: What is the next catalyst for XOMA Royalty CorporationShare Buyback & Accurate Intraday Trading Signals - baoquankhu1.vn
Analysts Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $60.60 - Defense World
Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 56.7% - MarketBeat
XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Analyzing XOMA Royalty (NASDAQ:XOMA) and Ascendis Pharma A/S (NASDAQ:ASND) - Defense World
Risk Off: What is the next catalyst for XOMA Royalty Corporation2025 Volume Leaders & Short-Term High Return Strategies - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance
XOMA Royalty Appoints New Chief Financial Officer - The Globe and Mail
Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com
XOMA Royalty Corp (NASDAQ: XOMA) appoints new CFO, sets pay terms - stocktitan.net
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com
XOMA royalty announces CFO transition - MSN
XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - Улправда
Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):